An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus  by Reimann, Ilona et al.
www.elsevier.com/locate/yviro
Virology 322 (2004) 143–157An avirulent chimeric Pestivirus with altered cell tropism protects
pigs against lethal infection with classical swine fever virus
Ilona Reimann,a Klaus Depner,b Sascha Trapp,c,1 and Martin Beerb,*
aFederal Research Center for Virus Diseases of Animals, Institute of Infectology, D-17493 Greifswald-Insel Riems, Germany
bFederal Research Center for Virus Diseases of Animals, Institute of Diagnostic Virology, D-17493 Greifswald-Insel Riems, Germany
cFederal Research Center for Virus Diseases of Animals, Institute of Molecular Biology, D-17493 Greifswald-Insel Riems, GermanyReceived 3 November 2003; returned to author for revision 25 November 2003; accepted 24 January 2004Abstract
A chimeric Pestivirus was constructed using an infectious cDNA clone of bovine viral diarrhea virus (BVDV) [J. Virol. 70 (1996) 8606].
After deletion of the envelope protein E2-encoding region, the respective sequence of classical swine fever virus (CSFV) strain Alfort 187
was inserted in-frame resulting in plasmid pA/CP7_E2alf. After transfection of in vitro-transcribed CP7_E2alf RNA, autonomous replication
of chimeric RNA in bovine and porcine cell cultures was observed. Efficient growth of chimeric CP7_E2alf virus, however, could only be
demonstrated on porcine cells, and in contrast to the parental BVDV strain CP7, CP7_E2alf only inefficiently infected and propagated in
bovine cells. The virulence, immunogenicity, and ‘‘marker vaccine’’ properties of the generated chimeric CP7_E2alf virus were determined
in an animal experiment using 27 pigs. After intramuscular inoculation of 1  107 TCID50, CP7_E2alf proved to be completely avirulent,
and neither viremia nor virus transmission to contact animals was observed; however, CSFV-specific neutralizing antibodies were detected
from day 11 after inoculation. In addition, sera from all animals reacted positive in an E2-specific CSFV-antibody ELISA, but were negative
for CSFV-ERNS-specific antibodies as determined with a CSFV marker ELISA. After challenge infection with highly virulent CSFV strain
Eystrup, pigs immunized with CP7_E2alf were fully protected against clinical signs of CSFV infection, viremia, and shedding of challenge
virus, and almost all animals scored positive in a CSFV marker ELISA. From our results, we conclude that chimeric CP7_E2alf may not only
serve as a tool for a better understanding of Pestivirus attachment, entry, and assembly, but also represents an innocuous and efficacious
modified live CSFV ‘‘marker vaccine’’.
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Introduction the Flaviviridae family (van Regenmortel et al., 2000). TheClassical swine fever (CSF) is listed within the highly
contagious OIE list A diseases of the Suidae (Anonymous,
1996), and infection of domestic pigs as well as wild boar
(Sus scrofa) is common. CSF is responsible for major
economic losses especially in countries with an industrial-
ized pig production (Artois et al., 2002; Edwards et al.,
2000; Vandeputte and Chappuis, 1999). It is caused by an
enveloped RNA virus that belongs to the genus Pestivirus of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.01.028
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bovine viral diarrhea (BVD) and border disease (BD).
Diseased animals show high fever and anorexia, and in late
stage, central nervous disorders. Necroscopies often reveal
hemorrhages in the mucosa and inner organs of diseased
animals.
The Pestivirus genome consists of a single-stranded
RNA of positive orientation. The RNA is approximately
12.3 kb long and encodes for one large open reading frame
(ORF), which is flanked by nontranslated regions (NTR) at
both ends of the genome (Collett, 1987; Ru¨menapf et al.,
1991). The Pestivirus ORF is translated into one polypro-
tein, which is co- and posttranslationally processed into 11
or 12 mature proteins by viral and cellular proteases. The
capsid protein C and the glycoproteins ERNS, E1, and E2 are
structural components of the virion (Ru¨menapf et al., 1991).
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homodimers (Weiland et al., 1990), and it may play a major
role in virus attachment and entry (Donis, 1995). Pestivirus
antibodies are directed against ERNS, E2, the nonstructural
protein NS3, and possibly envelope protein E1 (Donis and
Dubovi, 1987; Muyldermans et al., 1993). Neutralizing
activity was predominantly demonstrated for E2-specific
antibodies (Donis et al., 1988), but has also been discussed
for those directed against E1 and ERNS (Donis, 1995; Wei-
land et al., 1992). On the basis of amino acid sequence
analysis and determination of the N-termini, it was shown
that processing of E2 is mediated by a host cell signalase.
Typical hydrophobic signal sequences were identified up-
stream of the E2 N-terminus within E1-coding sequences,
and a transmembrane anchor of about 40 hydrophobic
amino acids was demonstrated at the C-terminus of E2
(Ru¨menapf et al., 1993).
The different Pestivirus species infect cells of ruminant or
porcine origin. However, the highest susceptibility and the
most efficient replication are observed in cells derived from
the homologous animal species (Ferrari, 1985; Mengeling
and Drake, 1969; Nettleton et al., 1998). Additionally, in
contrast to bovine viral diarrhea virus (BVDV) and border
disease virus (BVD), natural classical swine fever virus
(CSFV) infections are restricted to pigs (Liess and Moennig,
1990). Nevertheless, knowledge concerning the tropism of
Pestiviruses in vitro or in vivo is only fragmentary.
Because of the risk of CSFV transmission from the wild
boar population to domestic pigs (Artois et al., 2002) and
the high costs of the large scale culling associated with such
outbreaks (Vandeputte and Chappuis, 1999), the develop-
ment of new vaccines that allow a fast protection combined
with the possibility to differentiate infected from vaccinatedFig. 1. Schematic representation of the engineered constructs. Filled boxes repre
deleted regions and numbers indicate the nucleotide position in the BVDV full-len
Lines at the left and right ends indicate untranslated regions. Npro, autoprotease;
protein; NS2 to NS5, nonstructural proteins; 3V-NTR and 5V-NTR, noncoding reganimals is becoming increasingly important. Furthermore,
deliberate CSFV infection as an act of bioterrorism in
CSFV-free countries has to be taken into consideration.
Traditionally, for vaccination against CSFV infection, safe
and efficacious modified live vaccines using highly attenu-
ated CSFV strains (e.g., C-strain) have been used (Terpstra
and Robijns, 1977; Terpstra and Tielen, 1976). Neverthe-
less, following vaccination with the conventional modified
live vaccines, a serological distinction between vaccinated
animals and those reconvalescent from natural infection is
not possible. So-called marker or differentiating infected
from vaccinated animals (DIVA) vaccines in combination
with discriminating antibody assays allows differentiation of
infected animals and vaccinees (van Oirschot, 1999), and
recently, subunit marker vaccines based on baculovirus-
expressed CSFV E2 and some discriminating ELISA tests
based on the detection of ERNS antibodies have been
developed and used for the assessment of vaccine efficacy
and DIVA properties (de Smit, 2000; Hulst et al., 1993).
These studies revealed that the immune responses induced
by this particular subunit vaccine were considerably less
efficient compared with conventional live attenuated vac-
cines (Depner et al., 2001; Uttenthal et al., 2001).
Recent studies on new CSF vaccines have been facili-
tated by the availability of reverse genetic systems (Meyers
et al., 1996b; Moormann et al., 1996; Ru¨ggli et al., 1996)
that allow the directed manipulation of Pestivirus genomes.
Meyers et al. (1999) demonstrated that abrogating the
RNase activity in ERNS of CSFV led to attenuation, and
pigs immunized using the attenuated ERNS mutants were
fully protected from lethal challenge with virulent CSFV
strain Eystrup. Recently, chimeric Pestiviruses based on an
infectious DNA copy of the CSFV vaccine strain C (vansent the BVDV structural protein region. Horizontal dotted lines show the
gth genome. Arrows indicate restriction enzyme sites flanking the deletions.
C, capsid protein; ERNS, E1, and E2, envelope proteins; p7, nonstructural
ions. The scale is given in kb.
Fig. 2. (A) Passage history of chimeric Pestivirus CP7_E2alf using PK15
cells and whole freeze/thaw lysates. Endpoint titers are given as TCID50/ml.
First titers are from transfection supernatant (TF) collected at 24 h post-
transfection. (B) Crystal violet staining of PK15 cells at 96 h after infection
with 100 TCID50 CP7_E2alf. A cytopathic effect with virus plaques was
clearly visible in comparison to the uninfected control cell culture.
Table 1










ERNS 450c H!R 2/8
479c,d G!R 19/20
E1 686c L!H 9/16




a No amino acid exchanges could be detected for the capsid encoding
region.
b Eight to twenty clones of minimum of two different RT-PCR-products
were sequenced using the M13 forward and reverse primers.
c Amino acid position numbered according to BVDV CP7 (GenBank
accession number , BVU63479).
d The exchange at amino acid position 479 could be confirmed in a
consensus sequence using direct sequencing.
e Amino acid position numbered according to CSFVAlfort 187 (GenBank
accession number , X87939).
I. Reimann et al. / Virology 322 (2004) 143–157 145Gennip et al., 2000) were constructed. Replacement of the
antigenic region of E2 or of the complete ERNS gene of
CSFV strain C by the analogous sequences of BVDV type
II strain 5250 resulted in viable chimeric viruses, which
proved to be valuable tools for Pestivirus characterization
and could be used as a new type of genetically engineered
vaccine (de Smit et al., 2001).
Here we report on the construction of a chimeric Pesti-
virus, which is based on an infectious BVDV cDNA clone
(Meyers et al., 1996a), and expresses E2 from CSFV strain
Alfort 187 (Ru¨ggli et al., 1996) instead of BVDV E2. The
resulting chimeric virus CP7_E2alf was characterized in
vitro and in vivo. It could be demonstrated that CP7_E2alf
may not only serve as a tool for a better understanding of
Pestivirus infectivity and host range, but also represent an
innocuous and efficacious modified live CSFV ‘‘marker
vaccine’’. In comparison to other chimeric Pestiviruses,
our BVDV/CSFV chimera CP7_E2alf exhibits unique fea-
tures, especially regarding replication and cell tropism in
vitro and in vivo.Results
Cloning and recovery of the chimeric CP7_E2alf virus
A chimeric BVDV/CSFV full-length clone was con-
structed, in which the entire E2-coding region of cytopath-
ogenic BVDV strain CP7 was replaced by that of CSFV
strain Alfort 187 (Fig. 1). RNA transcribed from either pA/
CP7_DE2p7 or pA/CP7_DE2PacI (Fig. 1) was sufficient to
replicate after transfection in both KOP-R and PK15 cells
(data not shown). For recovery of chimeric CP7_E2alf virus,
RNA transcribed from the plasmid pA/CP7_E2alf was trans-
fected into KOP-R or PK15 cells. At 24 h after transfection,
CP7_E2alf virus progeny could be recovered from transfec-
tion supernatants of KOP-R and PK15 cells. RNA replication
and translation of NS3, E2, and ERNS were observed in both
cell types (data not shown). The specific infectivity of in
vitro-transcribed RNAwas determined after transfection of 1
 107 PK15, MDBK, or KOP-R cells with 1 Ag RNA. On
average, at 24 h post-transfection, RNA transcribed in vitro
from CP7_E2alf yielded 102.65 TCID50/Ag in PK15 cells,
101.375 TCID50/Ag in MDBK cells, and 101.75 TCID50/Ag
in KOP-R cells. At 12 h post-transfection, we observed 2.5
 105 fluorescing PK15 cells/Ag, 0.5  105 fluorescing
MDBK cells/Ag, and 1.25  105 fluorescing KOP-R cells/
Ag. However, efficient propagation of CP7_E2alf was
restricted to PK15 cells, and CP7_E2alf was serially
passaged on PK15 cells using lysates obtained after
freeze–thawing. Virus titers of every PK15 passage were
determined by end point titrations. During the first three
passages, the titer of CP7_E2alf declined from about 103.5
TCID50/ml to <10
1 TCID50/ml, but increased between
passages 4 and 8 to more than 1  106 TCID50/ml. After
eight passages, stable titers of approximately 107 TCID50/
ml could be detected (Fig. 2a). The 11th passage of
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characterization and for the immunization experiments.
Infection of PK15 cells with CP7_E2alf resulted in a
cytopathogenic effect, which developed at 4–6 days after
inoculation, dependent on the amount of virus used for
infection (Fig. 2b).
Transfection experiments with in vitro-transcribed
CP7_E2alf RNA performed with PK15 cells at 35, 37,Fig. 3. (A) IF analysis of PK15 cells infected with CP7_E2alf. The cells were stain
cell culture was IF-positive for the donor CSFV-E2, but negative for parental BVD
KOP-R and PK15 cells using BVDV-E2 (CA3/WB215) and CSFV-E2 (HC/TC 5
KOP-R and PK15 cells were subjected to SDS-Page (12% acrylamide) and subsequ
size could be detected in lysates of CP7_E2alf and CSFV Alfort 187-infected ce
infected KOP cells. ERNS protein could be detected in all infected cell lysates; how
CP7, which were different from the band pattern detected in the CSFVAlfort 187
proteins. Sizes are indicated in kilodaltons.and 39 jC did not reveal significant differences in the
obtained virus titers (data not shown).
Sequence comparison of the 1st and the 11th passage of
CP7_E2alf
To determine whether sequence changes occurred in
the region encoding the structural proteins (capsid, ERNS,ed using CSFV E2 (HC34) and BVDV E2 (CA3)-specific mab. The infected
V E2. Control cells remained negative. (B) Western blot analysis of infected
0)-specific mab as well as the panpesti anti-ERNS mab 01–03. Lysates of
ent protein transfer to a nitrocellulose membrane. CSFV E2 of the expected
ll cultures. BVDV E2 was exclusively detected in lysates of BVDV CP7-
ever, there was an identical single protein band for CP7_E2alf and BVDV
lysate. Control KOP-R and PK15 cell lysates were negative for E2 or ERNS
Fig. 4. (A) Multistep growth curves of chimeric CP7_E2alf, parental
BVDV CP7, and donor virus Alfort 187 in KOP-R and PK15 cells.
Confluent monolayers of PK15 or KOP-R cells were infected at a
multiplicity of infection (m.o.i.) of 1 and total freeze/thaw lysates were
titrated at 0, 8, 24, 48, 72, and 96 h after inoculation. Virus titers are given
as TCID50/ml in log 10 steps. (B) Plating efficiency of CP7_E2alf (11th
passage on PK15 cells), CP7, and Alfort 187 using porcine (PK15) and
bovine (KOP-R) cell cultures. Virus stocks were titrated in log 10 dilutions
on confluent monolayers of PK15 and KOP-R cells. Plating efficiency of
the different cell types was calculated as TCID50/ml. There was no
CP7_E2alf detectable after inoculation of KOP-R cells with 0.1 ml of a
1:10 diluted virus suspension (plating efficiency < 101.5 TCID50/ml). In
contrast, a high plating efficiency could be determined for CP7_E2alf after
inoculation of PK15 cells (106.875 TCID50/ml).
Fig. 5. (A) Cross-neutralization of 100 TCID50 CP7_E2alf versus porcine
antisera directed against CSFV strain Alfort 187, BVDV strain CP7, and
BDV strain 137/4. A high neutralizing antibody titer of 1:960 could be
detected for the anti-CSFV serum only. (B) Cross-neutralization of different
Pestiviruses in comparison to chimeric CP7_E2alf using CP7_E2alf (n = 5)
and CP7 (n = 5)-specific pig sera. CP7_E2alf-specific antisera exclusively
neutralized CSF viruses and the BVDV/CSFV chimera. In contrast,
neutralizing antibody titers against BVDV CP7 and to a lower extent to
BDV 137/4 were detectable with CP7-specific pig sera only.
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cells, the entire region encoding the structural proteins of
CP7_E2alf of the 1st and 11th passage was amplified by
using RT-PCR, and cloned into the pGEM-T Easy Vector
System (Promega). Eight to twenty different clones from
a minimum of two independent RT-PCRs were selectedand sequenced (Table 1). In 19 of 20 clones from
CP7_E2alf11th passage, an exchange at amino acid position
479 (numbered according to BVDV CP7), where a glycine
was changed into an arginine, could be detected (Table 1).
Other amino acid changes in the ERNS, E1, or E2 encoding
regions of the genome were detected in only 10–55% of
the sequenced plasmid clones (Table 1). No amino acid
changes could be detected in the capsid encoding region
(Table 1). The 479 Gly to Arg exchange is of special
interest because of the fact that amino acid position 479 of
CP7 and CP7_E2alf corresponds to amino acid position
476 of CSFV, which was demonstrated to play a key role in
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(Hulst et al., 2000). Using direct sequencing of the different
RT-PCR products with specific primers, only the 479 Gly to
Arg exchange was detected in the consensus sequence.
Characterization of the chimeric CP7_E2alf virus
The chimeric CP7_E2alf virus could be differentiated
from the parental BVDV strain CP7 by using the E2 protein
as a marker in IF and Western blotting (Fig. 3). Combining
the data of IF staining and Western blot analyses, the
chimeric CP7_E2alf virus displayed the expected pheno-
type, which was different from the parental BVDV strain
CP7 and the donor CSFV strain Alfort 187. Proteins of the
chimeric virus reacted with the CSFV E2-specific mab in
both IF and Western blots, but not with the BVDV E2 mab
(Figs. 3a, b). In addition, the Western blot analyses of
CP7_E2alf resulted in an E2 protein that was indistinguish-
able in size from the E2 of CSFV Alfort 187. The ERNS
proteins of CP7 and CP7_E2alf had an identical molecular
weight of approximately 48 kDa, although CSFVAlfort 187
ERNS showed the characteristic doublet pattern (Ru¨menapf
et al., 1991) (Fig. 3b). Furthermore, by using Western blot
analyses under nonreducing conditions, E2-homodimers as
well as chimeric E1–E2 heterodimers could be detected for
CP7_E2alf (data not shown).
Growth kinetics of the chimeric virus and both the donor
CSFV Alfort 187 and the parental BVDV CP7 were per-
formed in bovine KOP-R and porcine PK15 cells (Fig. 4a).Table 2
Virus isolation from blood leukocytes following immunization or challenge infec
aNumber of positive inoculations (1  106 leukocytes per inoculation, two inocul
gray, two positive samples = dark gray).
bVirus isolation of CSFV strain Eystrup on PK15 cells.
cVirus isolation of BVDV strain CP7 on KOP-R cells.
dAnimals were euthanized because of severe clinical symptoms.The multistep growth curve of Alfort 187 and CP7_E2alf
indicated a similar growth of both viruses in PK15 cells with
virus titers of more than 106 TCID50/ml at 96 h post-
infection (p.i.). However, a reduced growth rate with ap-
proximately threefold less maximum virus titers at 96 h p.i.
was determined for CP7_E2alf compared to Alfort 187 in
PK15 cells. In the same experiment, BVDV strain CP7 was
shown to replicate very inefficiently in PK15 cells, and
reached about 1000-fold less maximum end point titers
compared to CSFV Alfort 187 and CP7_E2alf (Fig. 4a).
Vice versa, CP7 reached titers of more than 106 TCID50/ml
on bovine KOP-R cells at 96 h p.i., although CP7_E2alf did
not replicate efficiently in KOP-R cells yielding more than
300-fold reduced end point titers (Fig. 4a). Replication of
CSFV Alfort 187 in KOP-R cells was marked delayed and
reduced compared to CP7; nevertheless, end point titers at
96 h p.i. were almost 20-fold higher than those of
CP7_E2alf. From these experiments, we concluded that
porcine PK15 cells supported efficient growth of chimeric
CP7_E2alf, but not of parental CP7 (Fig. 4a).
In addition, monolayers of KOP-R or PK15 cells were
infected with different dilutions of CP7_E2alf or CP7 to
determine the plating efficiency of both viruses on these
different cell types (Fig. 4b). It was demonstrated that
CP7_E2alf could easily infect PK15 cells (plating effi-
ciency: 106.875 TCID50/ml), although only single KOP-R
cells were infected even with the 1:10-diluted virus sus-
pension (plating efficiency: <101.5). Titration of CP7
resulted in a more than 10000-fold reduced plating effi-tion
ations per sample; no positive samples = white, one positive sample = light
Table 3
Serology post-immunization and challenge infection
Group Animal # Antibodya
(ND50, vs. Alfort/vs. CP7)
Marker
ELISA (%)
0 dpib 28 dpic 49–59 dpi 53 dpid
CP7_E2alf 2181 <2/<2 240/<2 5120/40 44
2182 <2/<2 120/<2 10240/30 72
2183 <2/<2 240/<2 10240/<2 53
2184 <2/<2 20/<2 10240/7 96
2185 <2/<2 60/<2 10240/40 76
Meane <2/<2 96/<2 8914/13 68
Contactf 2176 <2/<2 <2/<2 <2/<2 0
CP7_E2alf 2177 <2/<2 <2/<2 <2/<2 21
2178 <2/<2 <2/<2 <2/<2 12
2179 <2/<2 <2/<2 <2/<2 7
2180 <2/<2 <2/<2 <2/<2 13
<2/<2 <2/<2 <2/<2 11
CP7 2191 <2/<2 <2/640 960/>640 81
2192 <2/<2 <2/640 2560/>640 98
2193 <2/<2 <2/480 3840/>640 68
2194 <2/<2 <2/480 1920/>640 99
2195 <2/<2 <2/320 640/>640 72
<2/<2 <2/497 1633/>640 84
Contact CP7 2186 <2/<2 <2/<2 7/<2 6
2187 <2/<2 <2/<2 5/<2 10
2188 <2/<2 <2/<2 120/<2 100
2189 <2/<2 <2/40 <2/60 9
2190 <2/<2 <2/<2 7/<2 14
<2/<2 <2/2 8/2 28
Controls 2196 <2/<2 <2/<2 zg z
2197 <2/<2 <2/<2 320/5 79
2198 <2/<2 <2/<2 z z
2199 <2/<2 <2/<2 640/<2 99
2200 <2/<2 <2/<2 640/<2 91
2201 <2/<2 <2/<2 320/30 99
2202 <2/<2 <2/<2 z z
<2/<2 <2/<2 453/3 92
a Neutralizing antibody titer (ND50) against CSFV strain Alfort 187 and
BVDV strain CP7.
b Days post-immunization with chimeric CP7_E2alf or parental strain CP7.
c Day of challenge infection with CSFV strain Eystrup.
d ERNS blocking ELISA values in % at day 53 p. imm. (day 25 after
challenge).
e Geometric mean values of the neutralizing antibody titers.
f Contact animals (n = 5) were housed in close contact to the immunized
animals (CP7_E2alf and CP7) during the whole experiment.
g Animals were euthanized before day 49 post-immunization and did not
develop detectable neutralizing antibodies.
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the plating efficiency of the Alfort 187 virus on KOP-R
cells was more than 500-fold lower than that detected on
PK15 cells (Fig. 4b).
In cross-neutralization assays with antisera specific for
one certain Pestivirus species (anti-CSFV, anti-BVDV, and
anti-BDV), and with CP7_E2alf- and CP7-specific pig sera
collected at day 28 after immunization (sera from five
animals), a characteristic reaction pattern for CP7_E2alf
and the corresponding anti-CP7_E2alf serum was observed
(Figs. 5a, b). The CSFV-specific antiserum was able to
neutralize 100 TCID50 of CP7_E2alf with neutralization
titers of 1:960, although a serum containing high titers of
BVDV or BVD antibodies failed to do so. Using pig sera
obtained 4 weeks after immunization with CP7 or
CP7_E2alf, the chimeric CP7_E2alf as well as CSFV
strains Alfort 187 and Eystrup were readily neutralized by
the CP7_E2alf antiserum. In contrast, there was no detect-
able neutralizing effect of CP7_E2alf antisera versus BVDV
strain CP7 or BDV strain 137/4 (Fig. 5b). The CP7-specific
antisera were capable of neutralizing parental BVDV strain
CP7, but failed to neutralize the chimera as well as both
tested CSFV strains, whereas a weak neutralizing effect
against the BDV strain 137/4 could be determined (Fig. 5b).
Immunization and challenge infection of pigs
After immunization of pigs with the various viruses, the
general condition of the animals was good, irrespective of
the inoculum, and no clinical signs, leukopenia, or fever
were observed (data not shown). Virus isolation from blood
leukocytes after immunization was negative for all animals
in the CP7_E2alf group. In contrast, BVDV CP7 could be
isolated from two animals in the CP7 group (Table 2).
Serological screening with a CP7- or Alfort 187-specific
neutralization assay demonstrated that none of the
CP7_E2alf contact animals seroconverted, although one
animal in the CP7 contact group had a neutralizing antibody
titer of 1:40 against BVDV CP7 (Table 3). In conclusion,
neither a CP7_E2alf viremia nor shedding of the chimeric
virus to the contact animals could be observed. In contrast,
BVDV CP7 viremia was detectable in two of the immunized
animals, and serological data provided evidence that CP7
spread to one of the contact animals (Tables 2 and 3). Using
a CSFV-specific blocking ELISA for the detection of E2-
antibodies, all CP7_E2alf-immunized animals developed
positive signals with a mean value of more than 65% at
day 28 post-immunization (p. imm.; Fig. 6a). A first
serological reaction could be detected at day 11 p. imm.
for the CP7_E2alf group (Fig. 6a). No CSFV E2-specific
antibodies were detected in any of the sera from animals in
the CP7 group (Fig. 6a). By using a CP7- or Alfort 187-
specific neutralization assay, homologous antibody titers of
more than 1:10 could be detected in most of the CP7- and
CP7_E2alf-immunized animals at day 11 p. imm. At day 28
p. imm., mean titers of homologous neutralizing antibodieswere determined, which ranged from 1:100 for the
CP7_E2alf to 1:500 for the CP7 group (Fig. 6b, Table 3).
At day 28 p. imm., none of the animals in the CP7_E2alf
group had detectable CP7-specific antibodies and no Alfort
187-specific antibodies could be detected either in sera of
CP7-immunized pigs (Table 3).
After intramuscular challenge with the highly virulent
CSFV strain Eystrup at 28 days after immunization, the
health status of the pigs previously inoculated with
CP7_E2alf as well as that of the contact animals within
the CP7_E2alf group remained completely undisturbed, and
neither fever nor leukopenia were detectable in any of the
 
 
Fig. 6. (A) CSFV E2-specific ELISA antibodies after immunization with
CP7_E2alf or CP7. ELISA values are given in blocking percentages.
Samples with more than 30% blocking are scored positive. The mean
values (n = 5) of the CP7_E2alf and the CP7 group are given, and standard
deviations are shown as error bars. The mean values of sera of the CP7
group were negative until challenge infection, although the mean value of
the CP7_E2alf group scored positive with about 35% at day 11 p. imm. and
more than 60% at the day of challenge infection. (B) Homologous
neutralizing antibody titers after immunization with CP7_E2alf or CP7.
Mean values (n = 5) of the neutralizing titers of the CP7_E2alf and the CP7
group are given. Standard deviations are shown as error bars. The
homologous neutralizing antibody titers versus CP7_E2alf were deter-
mined using Alfort 187. The mean values (arithmetic mean) of CP7_E2alf-
immunized animals reached homologous titers of about 1:100 at day 28 p.
imm., while the CP7 group animals had a mean neutralizing titer of about
1:500 at the same time point.
Fig. 7. (A) Leukopenia after challenge infection with highly virulent CSFV
strain Eystrup. Mean values of the leukocyte counts of the CP7_E2alf
group (n = 5), the CP7 group (n = 5), and the control group (n = 7) are
given. Standard deviations are shown as error bars. (B) Body temperature
after challenge infection with highly virulent CSFV strain Eystrup. Mean
values of the rectal body temperature of the CP7_E2alf group (n = 5), the
CP7 group (n = 5), and the control group (n = 7) are given. Standard
deviations are shown as error bars.
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isolated from 2  106 blood leukocytes of any of the
CP7_E2alf-immunized animals between day 0 and 28 p.
chall. (Table 2). In addition, none of the CP7_E2alf contact
animals developed antibodies against CSFV or BVDV
(Table 3), suggesting that no virus shedding occurred or
shedding of challenge virus was too low to result in
infection of sentinel animals.
In contrast, all five pigs inoculated with BVDV strain
CP7 showed a rise of body temperature (>40 jC) and
significant leukopenia between days 3 and 9 after challengeinfection (Figs. 7a, b). Challenge virus could be isolated
from all animals of the CP7 group at different days p.i.
(Table 2). Uptake of feed was reduced during days 2 and 7
p. chall.; nevertheless, all five pigs fully recovered. One of
the contact animals in the CP7 group showed a rise in body
temperature between days 9 and 13 p. chall. (animal No.
2188), and CSFV challenge virus could be re-isolated from
blood leukocytes of animal No. 2188 (data not shown). Four
of the CP7 contact animals had CSFV-specific antibody
titers ranging between 1:5 and 1:120. One animal remained
CSFV seronegative, but showed a CP7-specific titer of 1:60
(Table 3).
All of the control pigs became anorectic and severely
depressed after CSFV inoculation. Typical CSF symptoms
I. Reimann et al. / Virology 322 (2004) 143–157 151started 3–4 days after challenge and lasted between 8 and
14 days. Uptake of feed was reduced during this period. A
severe leukopenia between days 4 and 14 p. chall. (Fig. 7a),
and fever with maximum body temperatures of more than
41.5 jC lasting for several days was observed (Fig. 7b).
Challenge virus could be re-isolated from blood leukocytes
of the control animals between days 2 and 11 after challenge
infection (Table 2). Three pigs were moribund (body tem-
perature > 41.5 jC, diarrhea, central nervous disorders) and
had to be euthanized on days 10 and 14 after challenge,
respectively. These animals did not develop any detectable
neutralizing antibodies against CSFV. The remaining pigs
recovered completely and CSFV-specific antibody titers
between 1:320 and 1:640 were determined (Table 3).
Differentiating infected from immunized animals
Following immunization and challenge infection, ‘‘mark-
er antibodies’’ were determined using a CSFV-specific ERNS
antibody blocking ELISA. In all pigs, the ERNS ELISA was
negative before but positive after challenge infection with
CSFV strain Eystrup (Table 3). After immunization and
before challenge infection, the mean ELISA values of the
CP7_E2alf group clearly were lower than 10% (Fig. 8).
After challenge infection, the mean blocking values of the
control and the CP7 groups scored positive with values of
more than 50% starting between days 11 and 14 p. chall.,
where seven out of nine animals were positive. In contrast,
four out of five sera from the CP7_E2alf group scored
negative at the same time point. At day 25 p. chall., the
mean ERNS ELISA value of the control animals (92%) wasFig. 8. Blocking ELISA analysis using a commercially available ELISA
system (Ceditest CSFV-ERNS; Cedi-Diagnostics, Netherlands). Mean
values of the ERNS blocking percentages of the CP7_E2alf group (n = 5),
the CP7 group (n = 5), and the control group (n = 7) are given. A serum is
scored positive with a percentage of more than 50% following the
manufacturers instructions. Standard deviations in percent are included as
error bars.higher than the ELISA percentages of the CP7 group (84%),
which in turn were higher than those of the animals of the
CP7_E2alf group (68%; Fig. 8, Table 3). The contact
animals remained negative until the end of the experiment,
except for one animal, which was clearly positive for CSFV-
specific ERNS antibodies (no. 2188; 100%, Table 3). These
results indicate that the CP7_E2alf-immunized pigs could be
differentiated from CSFV-infected animals and serocon-
verted with CSFV-ERNS-specific antibodies after a CSFV
challenge infection.Discussion
In this study, we describe the construction of a viable
BVDV/CSFV chimeric Pestivirus, in which BVDV E2
sequences were replaced with E2 sequences of CSFV strain
Alfort 187. Previously, several viable chimeric Pestiviruses
have been constructed, including some with exchanges in
the E2-coding region. Sequences encoding for the N-termi-
nal part of E2 or full-length ERNS from BVDV II were
inserted into an infectious CSFV genome (de Smit et al.,
2001; van Gennip et al., 2000), or border disease virus E2
replaced E2 of an infectious BVDV cDNA clone (Liang et
al., 2003). Expression of the here inserted CSFV E2 by
BVDV CP7 was detected using Western blot analysis and
indirect immunofluorescence; thus, the cytopathogenic chi-
meric CP7_E2alf could be easily distinguished from paren-
tal BVDV CP7 and donor CSFV strain Alfort 187 using
monoclonal antibodies.
Concerning replication and cell tropism, the generated
chimeric Pestiviruses reported so far displayed varying
phenotypes in vitro. The CSFV/BVDV chimera expressing
the N-terminal portion of BVDV II-derived E2 in a CSFV
background grew to virus titers, which were reduced not
more than 10-fold compared to wild-type CSFV in porcine
kidney cells (van Gennip et al., 2000). It was therefore
concluded that the replacement of the antigenic region of E2
did not change cellular tropism of C-strain-based CSF
viruses for porcine SK6 and bovine FBE cells. In contrast,
insertion of a sequence encoding full-length BDV E2 into
the BVDV genome resulted in a chimeric virus that
exhibited growth properties very similar to those of the
parental BDV that donated the E2 gene (Liang et al., 2003).
In one step growth kinetics, the end point titers of the
BVDV/BDV chimera after 24 h were reduced approximate-
ly 100-fold in bovine MDBK cells when compared to the
parental BVDV NADL. Nevertheless, all the reported
chimeric viruses could be easily propagated and further
passaged with the cell system used for the parental Pestivi-
rus. The BVDV/CSFV chimeric CP7_E2alf virus reported
here, however, could not be efficiently propagated using
bovine KOP-R cells, which usually yield the best titers for
parental BVDV CP7. Following RNA transfection, virus
replication and protein expression could be demonstrated,
and recombinant chimeric virus was detectable in the
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in vitro-transcribed CP7_E2alf RNAwas comparable to that
reported previously for infectious BVDV cDNA clones
(Ku¨mmerer and Meyers, 2000). However, the highest virus
titers could be obtained with PK15 cells, and further
propagation after transfection in KOP-R cells failed. In
addition, after passaging of the virus on porcine PK15 cells,
which are suitable for the propagation of the E2 donor
CSFV Alfort 187, the chimeric CP7_E2alf could be prop-
agated very efficiently. Nevertheless, in the first passages,
the titers decreased or remained low until passage eight,
when stable virus titers of more than 106 TCID50/ml could
be determined. Multistep growth analyses of the 11th PK15
passage revealed that CP7_E2alf replicates in KOP-R cells
with marked reduced end point titers compared to those of
BVDV CP7. In contrast, titers of chimeric CP7_E2alf in
PK15 cells were reduced only about threefold compared to
those of CSFV Alfort and almost 1000-fold higher than
those of BVDV CP7 on PK15 cells. Furthermore, plating
efficiency of CP7_E2alf was extremely reduced on KOP-R
cells in comparison to those determined on PK15 cells. In
conclusion, the reported exchange of BVDV E2 by CSFV
E2 in the CP7 genome resulted in a marked change of in
vitro host range of the chimeric virus compared to the
parental BVDV, and very closely resembled that of E2
donor strain CSFV Alfort 187.
The chimeric CP7_E2alf virus had to be passaged several
times on PK15 cells until stable and high virus titers were
reached. At passage 11, nucleotide sequence comparisons of
the entire structural genes (capsid, ERNS, E1, and E2) revealed
a predominant amino acid exchange at amino acid position
479 (according to the BVDV CP7 sequence), with the
uncharged amino acid glycine being exchanged by positively
charged arginine. Amino acid position 479 in the BVDV
genome corresponds to position 476 in the CSFV ERNS, for
which an identical exchange from an uncharged residue
(serine) to arginine was reported during adaptation of CSFV
strain Brescia to SK6 cells (Hulst et al., 2000). In the case of
CSFV Brescia, virus variants carrying this mutation were
able to attach to the surface of cells by the interaction with
membrane-associated heparan sulfate thus resulting in en-
hanced virus replication in vitro (Hulst et al., 2000, 2001). For
Sindbis virus, similar adaptations to the use of heparan sulfate
as an attachment receptor have been reported, and the
magnitude of binding was shown to be positively correlated
with the attenuation of these viruses (Klimstra et al., 1998).
However, a role of the described ERNS mutation for the
avirulence of CP7_E2alf is unlikely, because it was clearly
shown that the similar adaptive mutation had no effect on the
virulence of CSFV strain Brescia (Hulst et al., 2001). How-
ever, it may be speculated that the described mutation of
CP7_E2alf enabled a more efficient growth of CP7_E2alf in
porcine PK15 cells. Experiments specifically addressing this
hypothesis are currently ongoing.
The CP7_E2alf virus was then characterized by cross-
neutralization assays with antisera specific for differentPestivirus species. In these experiments, CP7_E2alf reacted
in a way that was indistinguishable from the E2 donor
strain Alfort 187, in that it was efficiently neutralized by a
CSFV-specific serum, but only marginally by sera with
high titers of BDV or BVDV type I neutralizing antibodies.
Vice versa, a CP7_E2alf-specific antiserum efficiently neu-
tralized different CSFV strains like Alfort 187 or Eystrup,
but did not have any effect on BVDV or BDV infection
(neutralization titer < 1:2). These results strongly support the
hypothesis that E2 might be the major or even the only
Pestiviral protein, able to induce detectable amounts of
neutralizing antibodies.
Upon inoculations of pigs, CP7_E2alf proved to be
completely apathogenic and did not spread to contact
animals. No virus was isolated from the infected animals,
and none of the sentinel pigs seroconverted, indicating that
CP7_E2alf has a very low potential for viremia and virus
shedding. In contrast, parental BVDV strain CP7 was re-
isolated from two of the CP7-immunized animals at day
4 p. imm., and one contact animal seroconverted with
CP7 neutralizing antibodies. The reduced replication of
CP7_E2alf in pigs was consistent with the reduced mean
neutralizing antibody titer of the animals immunized with
the chimeric virus, which was fourfold lower than that of
pigs inoculated with parental BVDV strain CP7. Therefore,
the in vivo growth properties seem to conflict to a certain
degree with the replication of chimeric CP7_E2alf and
parental CP7 in cultured cells. Insertion of CSFV E2 into
the BVDV background may enable the virus to efficiently
replicate in epitheloid PK15 cells, but impairs virus repli-
cation in cells, which are important for in vivo virus
shedding and spread. It is tempting to speculate that the
acquired ERNS mutation of CP7_E2alf, which is possibly
responsible for a better heparan sulfate binding, may com-
pensate for the loss of a specific CSFV-E2 function in cell
culture but not in the animal. It is known from in vitro
assays using bovine and porcine cell lines that E2 is the
major partner for receptor binding and attachment, with
CD46 as a binding partner (T. Ru¨menapf, personal commu-
nication), and recombinant E2 is able to block Pestivirus
infection in cultured cells (Hulst and Moormann, 1997). The
in vivo role of E2 concerning the interaction with specific
target cells, for example, leukocytes, however, is not well
understood. It has been shown that the E1–E2 heterodimer
may play an important role for a fully functional E2
(Ru¨menapf et al., 1993). Therefore, in the light of the data
presented here, a certain degree of incompatibility of BVDV
ERNS-E1 and CSFV E2 is likely, and the chimeric E1–E2
heterodimer of CP7_E2alf may be rendered less effective.
Contrary to our findings, the recently reported chimeric
Pestivirus mutants, in which BVDV II E2 or ERNS was
inserted into a CSFV background, induced a detectable
viremia and were transmitted to the contact animals (de
Smit et al., 2001). In conclusion, CP7_E2alf is highly
attenuated in pigs, although a clear in vitro adaptation to
porcine kidney cells was demonstrated. A restoration of
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because (i) the parental CP7 virus was shown to be avirulent
for pigs, (ii) no virus was shed to contact animals, (iii)
cytopathogenicity of CP7_E2alf leads to a self-limitation,
and (iv) the inserted CSFV E2 is obviously not a major
determinant of pathogenicity. Interestingly, the CSFV vac-
cine virus C-strain also efficiently replicates in porcine
kidney cells in vitro, but was demonstrated to be apatho-
genic for pigs inducing only limited viremia or virus spread,
which could be detected only in a fraction of inoculated
animals (Lorena et al., 2001; Terpstra et al., 1990). For a
better understanding of the in vivo cell tropism of the
chimeric virus, further in vitro infection studies with prima-
ry porcine cells and blood leukocytes are in progress, and
additional chimeric viruses have been constructed.
After challenge infection with highly virulent CSFV
strain Eystrup, all animals of the CP7_E2alf group were
completely protected, although all control animals devel-
oped severe CSF, and three animals had to be euthanized.
CP7-immunized animals exhibited an intermediate protec-
tion status after challenge infection. All animals developed
clinical signs like fever or leukopenia, but to a lower extent
than the naive control animals, and the animals in this group
recovered completely. However, challenge virus was trans-
mitted to four of the five contact animals. Titer differences
in the CP7 contact animals at day 56 p. chall. support the
conclusion that one initial contact infection subsequently
caused seroconversion of three additional contact animals.
Protection of BVDV-immunized pigs against clinical signs
of CSF was reported previously and is probably cell-
mediated, as no neutralizing antibodies were detectable (this
report) (Leforban et al., 1992; Overby, 1973; Simonyi and
Biro, 1967). In summary, CP7_E2alf immunization proved
to be as efficient and safe as the attenuated CSFV C-strain
(Biront et al., 1987; de Smit et al., 2001). In addition, we
conclude that E2 is the major immunogen for an effective
protection against highly virulent CSFV. In contrast to
baculovirus-expressed CSFV E2 (Uttenthal et al., 2001), a
single application was sufficient to achieve a complete
protection at day 28 p. imm. and neutralizing antibodies
could be observed as early as 11 days p. imm. Therefore, in
analogy to studies with the conventional C-strain vaccine
(Biront et al., 1987; Kaden et al., 2001) or a replication-
competent CSFV/BVDV chimera (de Smit et al., 2001),
protection at an earlier time point after immunization may
be possible.
Lastly, the results we obtained have shown that the
CP7_E2alf-induced ERNS-antibody pattern can be used for
discrimination between vaccinated and infected animals. At
day 25 p. chall., four pigs in the CP7_E2alf group were
clearly positive for ERNS antibodies, and one animal reacted
doubtful. Because of the fact that the highest ERNS antibody
responses in our experiment could be detected in the control
group, followed by the partially protected CP7 group, we
hypothesize that the one animal with a weak ERNS antibody
response in the CP7_E2alf group was so well protected bythe vaccine that replication of the challenge virus was
reduced to an extent that no detectable ERNS-specific hu-
moral immune response was mounted. Besides the pre-
sented possibility for serological differentiation, the
described BVDV/CSFV chimera has the advantage that
the genetic BVDV background can be used also for a direct
differentiation of the recombinant virus strain from wild-
type CSFVand CSFV vaccine strains by using real time RT-
PCR targeting regions of the Pestiviral genome that allow
species differentiation (McGoldrick et al., 1998, 1999).
The first BVDV/CSFV chimeric Pestivirus described in
this study had unique in vitro and in vivo characteristics. It
may prove not only useful for the understanding of Pesti-
viral cell tropism but also represents the basis for the
development of genetically engineered safe and effective
CSFV live marker vaccines. In the future, comprehensive
experiments will be performed to collect additional data on
virus replication as well as on the longevity of immunity,
vaccine efficiency after oral application, the protective
dosages, block of transplacental infection, and virus spread.Material and methods
Virus and cells
Porcine kidney cell line 15 (PK15; ATCC), Madin Darby
bovine kidney cells (MDBK, RIE261, CCLV), and KOP-R
cells (RIE244, CCLV), a diploid bovine esophageal cell
line, were obtained from the collection of cell lines in
veterinary medicine at the Federal Research Center of Virus
Diseases of Animals, Insel Riems (CCLV). Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% BVDV-free fetal bovine serum
(FBS). KOP-R cells were selected due to their susceptibility
to BVDV infection and their superior suitability for BVDV
propagation (Reimann et al., 2003).
CSFV strain Alfort 187 as well as the BDV strain 137/4
were obtained from the National Reference Laboratory for
CSF (Federal Research Centre for Virus Diseases of Ani-
mals, Insel Riems, Germany). Highly virulent CSFV strain
Eystrup was provided by Martin Hofman (IVI, Mittelha¨u-
sern, Switzerland). Cytopathogenic BVDV strain CP7 was
reconstituted after transfection of RNA transcribed from the
infectious cDNA clone pA/BVDV (Meyers et al., 1996a)
into KOP-R cells.
Monoclonal antibodies, antisera, ELISA, and neutralization
assays
For the detection of BVDV and CSFV proteins, the
monoclonal antibodies (mab) WB210 (anti-ERNS BVDV,
CVL Weybridge), 01–03 (anti-ERNS panpesti, kindly pro-
vided by Christian Schelp, Intervet BV), WB215 (anti-E2
BVDV, CVLWeybridge), CA3 (anti-E2 BVDV, Institute for
Virology, TiHo, Hannover), HC/TC50 (anti-E2 CSFV, In-
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Virology), mab-mix WB103/105 (anti-NS3 panpesti, CVL
Weybridge), and C16 (anti-NS3 panpesti, Institute for
Virology) were used (Edwards et al., 1988, 1991; Peters et
al., 1986). Standard immunofluorescence (IF) analysis using
a fluorescence-activated cell sorter (FACS; Becton Dick-
inson) or a fluorescence microscope (Olympus) were per-
formed as previously described (Beer et al., 1997; Grummer
et al., 2001).
Chimeric CP7_E2alf was tested in neutralization assays
with porcine hyperimmune sera directed against BDV,
BVDV, or CSFV, which were collected from experimentally
infected pigs (provided by the National Reference Labora-
tory for CSF, Insel Riems, Germany). Homologous neutral-
ization titers of the sera ranged from 1:640 to 1:960
neutralizing dosage 50% (ND50). In addition, sera from five
pigs sampled at day 28 post-infection with CP7_E2alf or
CP7, respectively, were used for cross-neutralization experi-
ments. Porcine sera free of Pestivirus-specific antibodies
served as controls. Standard neutralization assays using
inactivated sera were performed according to the OIE
manual (Anonymous, 1996) as previously described (Dep-
ner et al., 2001). Neutralization titers were determined as
neutralizing dosage 50%. In addition, serum or plasma
samples were tested for the presence of antibodies against
CSFV E2 and ERNS with the commercialized ELISA assays
HerdCheck CSFV AB (IDEXX) and Ceditest CSFV-ERNS
(Cedi-Diagnostics). Both test systems were used according
to the instructions given by the manufacturers.
Western blot analysis
Infected or uninfected KOP or PK15 cells (1.5  106)
were lysed by adding 300 Al of lysis buffer [1% Triton X-
100, 20 mM sodium phosphate (pH 7.1), 150 mM NaCl, 2
mM EDTA]. The cell lysate was cleared of cell debris by
low speed centrifugation at 10000  g for 5 min. Proteins in
20 Al of lysate were separated by 12% sodium-dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE),
and subsequently transferred onto a nitrocellulose mem-
brane (Schleicher and Schu¨ll). The membrane was incubat-
ed for 1 h at room temperature with anti-ERNS mab 01–03
(1:500), anti-E2 CSFV mab HC/TC50 (1:300), or anti-E2
mab BVDV CA3/WB215 (1:100) in TBST buffer (20 mMTable 4
PCR primers used for plasmid construction





a Restriction enzyme sites are underlined, overlaps to facilitate restriction enzyme
bold.
b Nucleotide position in CSFVAlfort 187 sequence.
c Nucleotide position in BVDV CP7 sequence.Tris–HCl, pH 7.5; 150 mM NaCl, 0.1% Tween 20). After
washing with TBST buffer, the membrane was incubated at
room temperature for 1 h with an anti-mouse immunoglob-
ulin G (IgG) conjugated to horseradish peroxidase (Dia-
nova; 1:30000). Following washing, the membrane was
incubated with SuperSignalR chemiluminescent detection
reagent (Pierce) and exposed to an X-ray film (Kodak).
In vitro transcription and electroporation
In vitro transcription of linearized full-length cDNA
constructs was performed by T7 RiboMax Large Scale
RNA Production System (Promega) according to the man-
ufacturer’s instructions. The amount of RNA was estimated
by ethidium bromide staining following agarose gel elec-
trophoresis. For transfections, 1  107 PK15 or KOP-R cells
were detached using a trypsin solution, washed with PBS,
mixed with 1–5 Ag of in vitro-synthesized RNA and trans-
fected (two pulses at 850 V, 25 AF, 156 V) using an
EasyjecT Plus (EquiBio) electroporation unit.
Polymerase chain reaction and sequencing
For polymerase chain reaction (PCR), a PTC-200 thermal
cycler (MJ Research, Inc.) was used. DNA-based amplifica-
tion was done by Expand High Fidelity PCR System (Roche
Molecular Biochemicals) according to the supplier’s proto-
col. Primers for generation of the respective constructs are
summarized in Table 4. For RT-PCR, total RNA of virus-
infected cells was extracted using the TRIZOL reagent
(Gibco-Life Technologies). cDNA was amplified from the
RNA template by using reverse transcriptase (AMV; Prom-
ega) and sequence-specific primers (Table 4). RNA for RT-
PCR experiments was treated with RNase-free DNases and
the RT step was omitted to detect contamination with cDNA.
The synthesized cDNA was amplified with a thermostable
Taq Polymerase (Promega) and resulting PCR products were
cloned into the pGEM-T Easy Vector System (Promega), or
directly sequenced. For sequence comparison of the region
encoding the structural proteins of CP7_E2alf1st passage and
CP7_E2alf11th passage, several fragments of the whole region
were cloned from a minimum of two different RT-PCR
products, and 8–20 different clones per fragment were
sequenced. In addition, the RT-PCR fragments were directlyGenomic region (nucleotides)
TT 2441–2462 (+ sense)b
3538–3559 ( sense)b
TCCAGTATGGGGCAGGTGA 3567–3586 (+ sense)c
3785–3804 ( sense)c
digestion are in italics and additional nucleotides for in-frame ligation are in
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population was determined.
Sequencing was carried out using a Thermo Sequenase
Cycle Sequencing Kit (Amersham Biosciences). Nucleotide
sequences were read with a LI-COR automatic sequencer
(MWG Biotech) and analyzed using the Wisconsin software
package version 9.1 (Genetics Computer Group, USA). For
sequencing of cloned DNA, M13 forward and reverse
primers as well as sequence-specific primers were used
(MWG Biotech).
Plasmid construction
The chimeric BVDV/CSFV clone shown in Fig. 1 was
constructed based on the full-length cDNA clone pA/BVDV
(kindly provided by Gregor Meyers, Federal Research Centre
for Virus Diseases of Animals, Tu¨bingen, Germany). BVDV-
specific restriction sites are indicated by superscript numbers
corresponding to their positions on the genome of BVDV
strain CP7, from which pA/BVDV (pA/CP7) was derived.
pA/CP7_DE2p7: Plasmid pA/BVDV was cleaved with
KpnI2447,3797 and religated, which resulted in an in-frame
deletion of E2 and p7 as shown previously (Reimann et al.,
2003).
pA/CP7_DE2PacI: In order to repair the p7 coding
region and insert a small polylinker (PacI, RsrII, SnaBI),
a PCR fragment was amplified using the primers p7-PacI
and p7R-KpnI (Table 4, Fig. 1). The PCR fragment was
cleaved with KpnI and cloned into the KpnI2447 site of
plasmid CP7DE2p7.
pA/CP7_E2alf: Plasmid pA/CP7_DE2PacI was digested
with PacI and SnaBI. For the purpose of generating a
CSFV-E2-expressing replicon, an RT-PCR-fragment was
amplified by using total cellular RNA of PK15 cells infected
with CSFV strain Alfort 187 and primers E2-Alfort-PacI
and E2R-Alfort-R-SnaBI (Table 4, Fig. 1). The PCR frag-
ment was digested with PacI and SnaBI, and subsequently
ligated in-frame into plasmid pA/CP7_DE2PacI (Fig. 1).
Recovery of Pestivirus from plasmid constructs and plaque
assay
For virus recovery, in vitro-transcribed RNA (1–5 Ag)
was transfected into PK15 or KOP-R cells by electro-
poration. Cell culture supernatants or complete cell lysates
after freezing/thawing were harvested at 24 h to 120 h
post-transfection (p. t.), and titrated using KOP-R or PK15
cells. At the day of supernatant collection, virus replica-
tion was monitored by IF staining. Virus preparations were
further passaged using PK15 or KOP-R cells, and all virus
titers were determined as TCID50. In all cases, the whole
virus population was passaged to avoid negative selection
that would be caused by biologically cloned virus. To
detect a possible temperature sensitivity, transfections of
CP7_E2alf RNA into PK15 cells were also incubated at
35, 37, and 39 jC.For the determination of both fluorescent cells/Ag elec-
troporated RNA and infectious units per Ag of RNA 1  107
PK15, MDBK and KOP-R cells were transfected in dupli-
cate with 1 Ag RNA. At 12 h post-transfection, all cell
cultures were IF-stained and the percentage of NS3-express-
ing cells was detected by FACS-analysis. At 24 h post-
transfection, supernatants of the transfected cell cultures
were titrated using PK15 cells.
In a standard plaque assay, cytopathogenicity of
CP7_E2alf was determined. PK15 cells were inoculated
with 100 TCID50 of CP7_E2alf, incubated for 1 h at 37 jC,
washed with PBS, and subsequently overlayed with meth-
yl cellulose (0.6% in DMEM). After 96 h incubation at 37
jC, the overlay was removed and the cells were stained with
crystal violet. Crystal violet staining was performed after
cells were washed once with PBS, fixed for 10 min with
5% formaldehyde, and washed again with water. For stain-
ing, the cells were incubated for 10 min with 1% (w/v)
crystal violet in 50% ethanol.
Multistep growth and plating efficiency
KOP-R cells or PK15 cells were infected with the various
viruses at a multiplicity of infection (m.o.i.) of 1 and
incubated for 0, 8, 24, 48, 72, and 96 h before harvesting
by freeze–thawing. Virus titers in TCID50/ml were deter-
mined by end point titration. CSFVAlfort 187 and chimeric
CP7_E2alf were titrated using PK15 cells; BVDV CP7 was
titrated in KOP-R cells.
For calculation of plating efficiency, the different virus
preparations were adjusted to a titer of 107 TCID50/ml in the
cell system, where the highest titers had been determined.
Subsequently, viruses were inoculated in KOP-R cells and
PK15 cells by limiting dilution (log 10 steps from 101 to
108; eight wells per dilution step) using 0.1 ml of the
diluted virus suspension per well in a 96 well plate.
Infection was detected by IF staining at 4 days post-
inoculation. Plating efficiency of the various viruses was
determined as TCID50/ml on the different cell types.
Animal experiments
Animals
Twenty-seven 6-week-old crossbredweanling pigs weigh-
ing approximately 12 kg each and free of neutralizing anti-
bodies against Pestiviruses were randomly divided into two
groups of 10 animals and one group of 7 animals. Five pigs
out of one group with 10 pigs were inoculated with
CP7_E2alf virus derived from infectious chimeric cDNA
clone pA/CP7_E2alf and challenged 28 days later with
virulent CSFV strain Eystrup (CP7_E2alf group). The
remaining five pigs from the group were kept as contact
animals. The inoculation procedure for the second group with
10 pigs (CP7 group) was analogous to that of the CP7_E2alf
group, differing only in the virus used for the first inoculation.
In this group, BVDV strain CP7 derived from infectious
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CP7_E2alf. In both groups, the contact animals were kept
apart from the inoculated pigs during the first three days after
inoculation with CP7_E2alf or CP7, respectively. The third
group (control group) was mock-immunized, and also chal-
lenged with 1  108 TCID50 of CSFV strain Eystrup at 28
days after inoculation. All pigs were inoculated intramuscu-
larly (i.m.) with 2 ml of cell culture supernatant containing
either 1  107 TCID50 of CP7_E2alf or 1  107 TCID50 of
CP7, respectively. The contact controls were left unchal-
lenged and housed in the same room with the respective
vaccination group.
During the course of the experiment, pigs were moni-
tored daily for clinical signs of CSF. Blood samples for
virological, serological, and hematological examinations
were taken by venipuncture in weekly intervals before and
after primary inoculation or challenge, respectively. Mori-
bund animals were euthanized and necropsied, as were the
healthy animals 9 weeks after the start of the experiment.
Virus was isolated from blood samples by using coculti-
vation of 1  106 blood leukocytes with PK15 or KOP-R
cells for 5–6 days in duplicate. After an incubation period of
5–6 days, the cells were analyzed for NS3 expression by IF.Acknowledgments
We thank Doreen Reichelt, Gabriela Adam, Ulrike
Polenz, and Barbara Herzog for excellent technical assis-
tance, and Christian Schelp (Bommeli Diagnostics, Bern,
Switzerland) as well as Irene Greiser-Wilke (TiHo, Hann-
over, Germany) for providing NS3, ERNS, and E2-specific
antibodies. The skilled efforts of the animal technicians and
of the head of the animal unit, Elke Lange, are greatly
appreciated. We are also grateful to Martin Hofmann (IVI,
Mittelha¨usern, Switzerland) for providing the CSFV strain
Eystrup, to Gregor Meyers for the infectious BVDV clone
pA/BVDV, and to Nikolaus Osterrieder for helpful dis-
cussions and critical reading of the manuscript.References
Anonymous, 1996. OIE Manual of Standards for Diagnostic Tests and
Vaccines. List A and B Diseases of Mammals, Birds and Bees, 3rd
ed., Off. Int. Epiz, Paris, pp. 145–154.
Artois, M., Depner, K.R., Guberti, V., Hars, J., Rossi, S., Rutili, D., 2002.
Classical swine fever (hog cholera) in wild boar in Europe. Rev. Sci.
Tech. 21, 287–303.
Beer, M., Wolf, G., Pichler, J., Wolfmeyer, A., Kaaden, O.R., 1997. Cyto-
toxic T-lymphocyte responses in cattle infected with bovine viral diar-
rhea virus. Vet. Microbiol. 58, 9–22.
Biront, P., Leunen, J., Vandeputte, J., 1987. Inhibition of virus replication
in the tonsils of pigs previously vaccinated with a Chinese strain vac-
cine and challenged oronasally with a virulent strain of classical swine
fever virus. Vet. Microbiol. 14, 105–113.
Collett, M.S., 1987. Molecular genetics of Pestivirus. Comp. Immunol.
Microbiol. Infect. Dis. 15, 145–154.de Smit, A.J., 2000. Laboratory diagnosis, epizootiology, and efficacy
of marker vaccines in classical swine fever: a review. Vet. Q. 22,
182–188.
de Smit, A.J., Bouma, A., van Gennip, H.G., de Kluijver, E.P., Moormann,
R.J., 2001. Chimeric marker C-strain viruses induce clinical protection
against virulent classical swine fever virus CSFV and reduce transmis-
sion of CSFV between vaccinated pigs. Vaccine 19, 1467–1476.
Depner, K.R., Bouma, A., Koenen, F., Klinkenberg, D., Lange, E., de Smit,
H., Vanderhallen, H., 2001. Classical swine fever (CSF) marker vac-
cine. Trial II. Challenge study in pregnant sows. Vet. Microbiol. 83,
107–120.
Donis, R.O., 1995. Molecular biology of bovine viral diarrhea virus and its
interactions with the host. Vet. Clin. North Am.: Food Anim. Pract. 11,
393–423.
Donis, R.O., Dubovi, E.J., 1987. Molecular specificity of the antibody
responses of cattle naturally and experimentally infected with cytopath-
ic and noncytopathic bovine viral diarrhea virus biotypes. Am. J. Vet.
Res. 48, 1549–1554.
Donis, R.O., Corapi, W., Dubovi, E.J., 1988. Neutralizing monoclonal
antibodies to bovine viral diarrhoea virus bind to the 56K to 58K
glycoprotein. J. Gen. Virol. 69, 77–86.
Edwards, S., Sands, J.J., Harkness, J.W., 1988. The application of mono-
clonal antibody panels to characterize Pestivirus isolates from ruminants
in Great Britain. Arch. Virol. 102, 197–206.
Edwards, S., Moennig, V., Wensvoort, G., 1991. The development of an
international reference panel of monoclonal antibodies for the differen-
tiation of hog cholera virus from other Pestiviruses. Vet. Microbiol. 29,
101–108.
Edwards, S., Fukusho, A., Lefevre, P.C., Lipowski, A., Pejsak, Z., Roehe,
P., Westergaard, J., 2000. Classical swine fever: the global situation.
Vet. Microbiol. 73, 103–119.
Ferrari, M., 1985. Susceptibility of various cell culture systems to bovine
viral diarrhea virus. Microbiologica 8, 17–22.
Grummer, B., Beer, M., Liebler-Tenorio, E., Greiser-Wilke, I., 2001.
Localization of viral proteins in cells infected with bovine viral diar-
rhoea virus. J. Gen. Virol. 82, 2597–2605.
Hulst, M.M., Moormann, R.J., 1997. Inhibition of Pestivirus infection in
cell culture by envelope proteins E(rns) and E2 of classical swine fever
virus: E(rns) and E2 interact with different receptors. J. Gen. Virol. 78,
2779–2787.
Hulst, M.M., Westra, D.F., Wensvoort, G., Moormann, R.J., 1993. Glyco-
protein E1 of hog cholera virus expressed in insect cells protects swine
from hog cholera. J. Virol. 67, 5435–5442.
Hulst, M.M., van Gennip, H.G., Moormann, R.J., 2000. Passage of classi-
cal swine fever virus in cultured swine kidney cells selects virus var-
iants that bind to heparan sulfate due to a single amino acid change in
envelope protein E(rns). J. Virol. 74, 9553–9561.
Hulst, M.M., van Gennip, H.G., Vlot, A.C., Schooten, E., de Smit, A.J.,
Moormann, R.J., 2001. Interaction of classical swine fever virus with
membrane-associated heparan sulfate: role for virus replication in vivo
and virulence. J. Virol. 75, 9585–9595.
Kaden, V., Schurig, U., Steyer, H., 2001. Oral immunization of pigs against
classical swine fever. Course of the disease and virus transmission after
simultaneous vaccination and infection. Acta Virol. 45, 23–29.
Klimstra, W.B., Ryman, K.D., Johnston, R.E., 1998. Adaptation of Sindbis
virus to BHK cells selects for use of heparan sulfate as an attachment
receptor. J. Virol. 72, 7357–7366.
Ku¨mmerer, B.M., Meyers, G., 2000. Correlation between point mutations
in NS2 and the viability and cytopathogenicity of bovine viral diarrhea
virus strain Oregon analyzed with an infectious cDNA clone. J. Virol.
74, 390–400.
Leforban, Y., Vannier, P., Cariolet, R., 1992. Protection of piglets born from
ruminant Pestivirus experimentally infected sows, and their contacts, to
the challenge with hog cholera virus. Ann. Rech. Vet. 23, 73–82.
Liang, D., Sainz, I.F., Ansari, I.H., Gil, L.H., Vassilev, V., Donis, R.O.,
2003. The envelope glycoprotein E2 is a determinant of cell culture
tropism in ruminant Pestiviruses. J. Gen. Virol. 84, 1269–1274.
I. Reimann et al. / Virology 322 (2004) 143–157 157Liess, B., Moennig, V., 1990. Ruminant Pestivirus infection in pigs. Rev.
Sci. Tech. 9, 151–161.
Lorena, J., Barlic-Maganja, D., Lojkic, M., Madic, J., Grom, J., Cac, Z.,
Roic, B., Terzic, S., Lojkic, I., Polancec, D., Cajavec, S., 2001. Classi-
cal swine fever virus (C strain) distribution in organ samples of inoc-
ulated piglets. Vet. Microbiol. 81, 1–8.
McGoldrick, A., Lowings, J.P., Ibata, G., Sands, J.J., Belak, S., Paton, D.J.,
1998. A novel approach to the detection of classical swine fever virus
by RT-PCR with a fluorogenic probe (TaqMan). J. Virol. Methods 72,
125–135.
McGoldrick, A., Bensaude, E., Ibata, G., Sharp, G., Paton, D.J., 1999.
Closed one-tube reverse transcription nested polymerase chain reaction
for the detection of Pestiviral RNA with fluorescent probes. J. Virol.
Methods 79, 85–95.
Mengeling, W.L., Drake, L., 1969. Replication of hog cholera virus in cell
culture. Am. J. Vet. Res. 30, 1817–1823.
Meyers, G., Tautz, N., Becher, P., Thiel, H.J., Ku¨mmerer, B.M., 1996a.
Recovery of cytopathogenic and noncytopathogenic bovine viral diar-
rhea viruses from cDNA constructs. J. Virol. 70, 8606–8613.
Meyers, G., Thiel, H.J., Ru¨menapf, T., 1996b. Classical swine fever virus:
recovery of infectious viruses from cDNA constructs and generation of
recombinant cytopathogenic defective interfering particles. J. Virol. 70,
1588–1595.
Meyers, G., Saalmu¨ller, A., Bu¨ttner, M., 1999. Mutations abrogating the
RNase activity in glycoprotein E(rns) of the Pestivirus classical swine
fever virus lead to virus attenuation. J. Virol. 73, 10224–10235.
Moormann, R.J., van Gennip, H.G., Miedema, G.K., Hulst, M.M., van
Rijn, P.A., 1996. Infectious RNA transcribed from an engineered
full-length cDNA template of the genome of a Pestivirus. J. Virol.
70, 763–770.
Muyldermans, G., Caij, A., De Smet, A., Koenen, F., Hamers, R., 1993.
Characterization of structural and non-structural proteins of hog cholera
virus by means of monoclonal antibodies. Arch. Virol. 131, 405–417.
Nettleton, P.F., Gilray, J.A., Russo, P., Dlissi, E., 1998. Border disease of
sheep and goats. Vet. Res. 29, 327–340.
Overby, G., 1973. Immunization against swine fever with a Danish bovine
viral diarrhoea virus strain, UG 59. Nord. Veterinaermed. 25, 497–503.
Peters, W., Greiser, W.I., Moennig, V., Liess, B., 1986. Preliminary sero-
logical characterization of bovine viral diarrhoea virus strains using
monoclonal antibodies. Vet. Microbiol. 12, 195–200.
Reimann, I., Meyers, G., Beer, M., 2003. Trans-complementation of auton-
omously replicating Bovine viral diarrhea virus replicons with deletions
in the E2 coding region. Virology 307, 213–227.
Ru¨ggli, N., Tratschin, J.D., Mittelholzer, C., Hofmann, M.A., 1996. Nu-cleotide sequence of classical swine fever virus strain Alfort/187 and
transcription of infectious RNA from stably cloned full-length cDNA.
J. Virol. 70, 3478–3487.
Ru¨menapf, T., Meyers, G., Stark, R., Thiel, H.J., 1991. Molecular charac-
terization of hog cholera virus. Arch. Virol. (Suppl. 3), 7–18.
Ru¨menapf, T., Unger, G., Strauss, J.H., Thiel, H.J., 1993. Processing of the
envelope glycoproteins of Pestiviruses. J. Virol. 67, 3288–3294.
Simonyi, E., Biro, J., 1967. Immunization experiments against hog cholera
with the bovine viral diarrhoea virus strain Oregon C24V. Acta Vet.
Acad. Sci. Hung. 17, 55–61.
Terpstra, C., Robijns, K.G., 1977. Experience with regional vaccination
against swine fever in enzootic areas for limited periods using C-strain
virus. Tijdschr. Diergeneeskd. 102, 106–112.
Terpstra, C., Tielen, M.J., 1976. Antibody response against swine fever
following vaccination with C-strain virus. Zentralbl. Veterinaermed.,
Reihe B 23, 809–821.
Terpstra, C., Woortmeyer, R., Barteling, S.J., 1990. Development and pro-
perties of a cell culture produced vaccine for hog cholera based on the
Chinese strain. Dtsch. Tieraerztl. Wochenschr. 97, 77–79.
Uttenthal, A., Le Potier, M.F., Romero, L., De Mia, G.M., Floegel-Nies-
mann, G., 2001. Classical swine fever (CSF) marker vaccine. Trial I.
Challenge studies in weaner pigs. Vet. Microbiol. 83, 85–106.
Vandeputte, J., Chappuis, G., 1999. Classical swine fever: the Euro-
pean experience and a guide for infected areas. Rev. Sci. Tech. 18,
638–647.
van Gennip, H.G., van Rijn, P.A., Widjojoatmodjo, M.N., de Smit, A.J.,
Moormann, R.J., 2000. Chimeric classical swine fever viruses contain-
ing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus
protect pigs against challenge with CSFV and induce a distinguishable
antibody response. Vaccine 19, 447–459.
van Oirschot, J.T., 1999. Diva vaccines that reduce virus transmission.
J. Biotechnol. 73, 195–205.
van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L., Carstens, E.B.,
Estes, M.K., Lemon, S.M., Maniloff, M.A., Mayo, D.J., McGeoch,
D.J., Pringle, C.R., Wickner, R.B., 2000. Virus Taxonomy. Seventh
Report of the International Committee on Taxonomy of Viruses. Aca-
demic Press, San Diego, CA.
Weiland, E., Stark, R., Haas, B., Ru¨menapf, T., Meyers, G., Thiel,
H.J., 1990. Pestivirus glycoprotein which induces neutralizing anti-
bodies forms part of a disulfide-linked heterodimer. J. Virol. 64,
3563–3569.
Weiland, E., Ahl, R., Stark, R., Weiland, F., Thiel, H.J., 1992. A second
envelope glycoprotein mediates neutralization of a Pestivirus, hog cho-
lera virus. J. Virol. 66, 3677–3682.
